Pradaxa Approved to Treat VTE, Concerns Linger
Several media outlets are reporting that Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa use to treat venous thromboembolism (VTE), which includes both deep venous thrombosis (DVT) and pulmonary embolism (PE).
The manufacturer released a statement saying that the approval is for patients who have been treated with a parenteral anticoagulant for five to 10 days. It estimates that there are 900,000 DVT and PE events per year in the U.S.
I Have Been Injured By Pradaxa
Although the FDA has approved the use of Pradaxa for venous thromboembolism, it does not mean that there are not associated side effects.
Pradaxa has been approved to treat atrial fibrillation, although it has been linked to internal bleeding, gastrointestinal bleeding, kidney bleeding, digestive track ulcers, brain hemorrhaging and death. For more information, you can visit our Pradaxa side effects page.
Our lawyers represent victims of dangerous medical devices and drugs like Pradaxa, defective medical devices and consumer products. Contact our experienced attorneys by calling toll-free (888)841-9623 today.
Zoll, Kranz & Borgess, LLC – Pradaxa attorneys